Arcadia Biosciences Logo
US0390142042
A2JSFW
RKDA

Arcadia Biosciences

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 5,47 (+3.117,65%). A mediana é € 5,47 (+3.117,65%).

Comprar
  4
Manter
  1
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Mais em de.investing.com


  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Mais em de.investing.com


  • Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

    Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Mais em de.investing.com


  • Arcadia Biosciences stock rises after termination of Roosevelt deal

    Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Mais em de.investing.com


  • Arcadia Biosciences schedules annual general meeting for December 19, 2025

    Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Arcadia Biosciences registou receitas de € 1,43 mi e um ganho líquido de € 1,55 mi
(EUR) setembro de 2026
YoY
Receitas 1,43 mi 28,83%
Ganho bruto 758,37 mil 112,91%
Ganho líquido 1,55 mi 112,41%
EBITDA 1,55 mi 111,92%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 281,57 mil
Número de ações
1,55 mi
Máximo/mínimo de 52 semanas
€ 3,53 - € 0,10
Dividendos Não
Beta
0,59
PER (PE Ratio)
-0,02
PEG (PEG Ratio)
0,00
P/VC (PB Ratio)
0,50
P/V (PS Ratio)
0,06

Perfil da empresa

A Arcadia Biosciences, Inc. produz e comercializa produtos de saúde e bem-estar de origem vegetal nos Estados Unidos. A empresa dedica-se ao desenvolvimento de melhorias em culturas, sobretudo de trigo, para aumentar a rentabilidade agrícola, melhorando o desempenho das culturas no campo, bem como o seu valor como ingredientes alimentares, produtos de saúde e bem-estar, e a sua viabilidade para aplicações industriais. A empresa foi constituída em 2002 e tem sede em Davis, Califórnia.

Nome
Arcadia Biosciences
CEO
Thomas J. Schaefer
Sede Davis, tx
EUA
Site
Setor
Bens de consumo básico
Indústria
Produtos alimentares
Entrada em bolsa
15/05/2015
Colaboradores 8

Símbolos de ticker

Bolsa Símbolo
NASDAQ
RKDA
Frankfurt
17DN.F
München
17DN.MU
🍪

Parqet  utiliza cookies. Saber mais